PMID- 34599661 OWN - NLM STAT- MEDLINE DCOM- 20220225 LR - 20231116 IS - 1432-1041 (Electronic) IS - 0031-6970 (Print) IS - 0031-6970 (Linking) VI - 78 IP - 1 DP - 2022 Jan TI - Sports nutrition supplements and adverse events - a meta-epidemiological study of case reports specifically addressing causality assessment. PG - 1-9 LID - 10.1007/s00228-021-03223-9 [doi] AB - PURPOSE: This meta-epidemiological study aimed to systematically review case reports regarding sports nutrition supplements and adverse events (AEs), specifically addressing the issue of causality assessments. METHODS: Through a systematic literature search we identified all published case reports of AEs associated with sports nutrition supplements between 1 January 2008 and 1 March 2019. Data regarding AEs, suspected supplements, relevant causality assessment factors and the reporting of clinical reasoning and/or systematic causality assessment methods were extracted. RESULTS: In all, 72 publications were included, reporting 134 supplements and 37 different AEs in 97 patients (85% males; median age: 30 years [range: 14-60]). Information regarding previous health and regular prescription drugs was not presented in 30% (29/97) and 46% (45/97) of cases, respectively. In 23% (22/97) of the cases, no alternative cause was mentioned. Clinical reasoning was identified in 63% (61/97), and in 13% (8/61) of these, a systematic causality assessment method was applied. In cases with clinical reasoning, a theoretic rationale (92% vs 78%, P = 0.05), a description of previous cases (90% vs 72%, P = 0.021) and body fluid analysis (18% vs 3%, P = 0.027) were reported to a greater extent. Among cases with clinical reasoning, the application of a systematic causality assessment method captured additional important aspects: use of medication (100% vs 55%, P = 0.015), alcohol use (88% vs 43%, P = 0.020) and illicit drug use (88% vs 40%, P = 0.011). CONCLUSIONS: In published case reports where sports nutrition supplements were suspected to have caused AEs, essential factors for causality assessment were left out in a non-negligible proportion. Clinical reasoning was identified in most cases whereas a systematic causality assessment method was applied in a minority. Factors of importance for causality assessment were reported to a greater extent in cases including clinical reasoning, and the application of a systematic causality assessment method captured additional aspects of importance. CI - (c) 2021. The Author(s). FAU - Zeijlon, Rickard AU - Zeijlon R AD - Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. rickard.zeijlon@gu.se. AD - Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. rickard.zeijlon@gu.se. FAU - Hantelius, Victor AU - Hantelius V AD - Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Wallerstedt, Susanna M AU - Wallerstedt SM AD - Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - HTA-Centrum, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Holmqvist, Lina AU - Holmqvist L AD - Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Gothenburg Emergency Medicine Research Group, GEMREG, Sahlgrenska University Hospital, Gothenburg, Sweden. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211002 PL - Germany TA - Eur J Clin Pharmacol JT - European journal of clinical pharmacology JID - 1256165 SB - IM MH - Adolescent MH - Adult MH - Causality MH - Dietary Supplements/*adverse effects MH - Epidemiologic Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Sports Nutritional Sciences MH - Young Adult PMC - PMC8724217 OTO - NOTNLM OT - Adverse event OT - Causality assessment OT - Clinical reasoning OT - Dietary supplement COIS- Rickard Zeijlon, Victor Hantelius, Susanna M. Wallerstedt and Lina Holmqvist declare that they have no conflicts of interest. EDAT- 2021/10/03 06:00 MHDA- 2022/02/26 06:00 PMCR- 2021/10/02 CRDT- 2021/10/02 12:03 PHST- 2021/03/05 00:00 [received] PHST- 2021/07/30 00:00 [accepted] PHST- 2021/10/03 06:00 [pubmed] PHST- 2022/02/26 06:00 [medline] PHST- 2021/10/02 12:03 [entrez] PHST- 2021/10/02 00:00 [pmc-release] AID - 10.1007/s00228-021-03223-9 [pii] AID - 3223 [pii] AID - 10.1007/s00228-021-03223-9 [doi] PST - ppublish SO - Eur J Clin Pharmacol. 2022 Jan;78(1):1-9. doi: 10.1007/s00228-021-03223-9. Epub 2021 Oct 2.